Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

Ele Ferrannini, Ralph A Defronzo

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two-to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular risk factors (CVRFs) and reduce cardiovascular morbidity and mortality. In this review, we examine the effect of oral (metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP4 inhibitors, SGLT2 inhibitors, and α-glucosidase inhibitors) and injectable (glucagon-like peptide-1 receptor agonists and insulin) glucose-lowering drugs on established CVRFs and long-term studies of cardiovascular outcomes. Firm evidence that in T2DM cardiovascular disease can be reversed or prevented by improving glycaemic control is still incomplete and must await large, long-term clinical trials in patients at low risk using modern treatment strategies, i.e. drug combinations designed to maximize HbA<inf>1c</inf> reduction while minimizing hypoglycaemia and excessive weight gain.

Original languageEnglish (US)
Pages (from-to)2288-2296
Number of pages9
JournalEuropean Heart Journal
Volume36
Issue number34
DOIs
StatePublished - Sep 7 2015

Fingerprint

Type 2 Diabetes Mellitus
Cardiovascular Diseases
Glucose
Pharmaceutical Preparations
Glucosidases
Multiple Abnormalities
Thiazolidinediones
Metformin
Drug Combinations
Hypoglycemia
Weight Gain
Reference Values
Stroke
Myocardial Infarction
Outcome Assessment (Health Care)
Clinical Trials
Insulin
Morbidity
Injections
Mortality

Keywords

  • Cardiovascular disease
  • Cardiovascular risk
  • Glucose-lowering drugs
  • Type 2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. / Ferrannini, Ele; Defronzo, Ralph A.

In: European Heart Journal, Vol. 36, No. 34, 07.09.2015, p. 2288-2296.

Research output: Contribution to journalArticle

@article{8154b9784b32491a9c93420b5db8ad12,
title = "Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes",
abstract = "Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two-to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular risk factors (CVRFs) and reduce cardiovascular morbidity and mortality. In this review, we examine the effect of oral (metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP4 inhibitors, SGLT2 inhibitors, and α-glucosidase inhibitors) and injectable (glucagon-like peptide-1 receptor agonists and insulin) glucose-lowering drugs on established CVRFs and long-term studies of cardiovascular outcomes. Firm evidence that in T2DM cardiovascular disease can be reversed or prevented by improving glycaemic control is still incomplete and must await large, long-term clinical trials in patients at low risk using modern treatment strategies, i.e. drug combinations designed to maximize HbA1c reduction while minimizing hypoglycaemia and excessive weight gain.",
keywords = "Cardiovascular disease, Cardiovascular risk, Glucose-lowering drugs, Type 2 diabetes",
author = "Ele Ferrannini and Defronzo, {Ralph A}",
year = "2015",
month = "9",
day = "7",
doi = "10.1093/eurheartj/ehv239",
language = "English (US)",
volume = "36",
pages = "2288--2296",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "34",

}

TY - JOUR

T1 - Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

AU - Ferrannini, Ele

AU - Defronzo, Ralph A

PY - 2015/9/7

Y1 - 2015/9/7

N2 - Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two-to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular risk factors (CVRFs) and reduce cardiovascular morbidity and mortality. In this review, we examine the effect of oral (metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP4 inhibitors, SGLT2 inhibitors, and α-glucosidase inhibitors) and injectable (glucagon-like peptide-1 receptor agonists and insulin) glucose-lowering drugs on established CVRFs and long-term studies of cardiovascular outcomes. Firm evidence that in T2DM cardiovascular disease can be reversed or prevented by improving glycaemic control is still incomplete and must await large, long-term clinical trials in patients at low risk using modern treatment strategies, i.e. drug combinations designed to maximize HbA1c reduction while minimizing hypoglycaemia and excessive weight gain.

AB - Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two-to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular risk factors (CVRFs) and reduce cardiovascular morbidity and mortality. In this review, we examine the effect of oral (metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP4 inhibitors, SGLT2 inhibitors, and α-glucosidase inhibitors) and injectable (glucagon-like peptide-1 receptor agonists and insulin) glucose-lowering drugs on established CVRFs and long-term studies of cardiovascular outcomes. Firm evidence that in T2DM cardiovascular disease can be reversed or prevented by improving glycaemic control is still incomplete and must await large, long-term clinical trials in patients at low risk using modern treatment strategies, i.e. drug combinations designed to maximize HbA1c reduction while minimizing hypoglycaemia and excessive weight gain.

KW - Cardiovascular disease

KW - Cardiovascular risk

KW - Glucose-lowering drugs

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84941243068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941243068&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehv239

DO - 10.1093/eurheartj/ehv239

M3 - Article

VL - 36

SP - 2288

EP - 2296

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 34

ER -